Executing Patient-Focused Drug Development (PFDD)

Veristat's Science Advisory Board convened on March 14, 2023, to deliberate on the implementation of Patient-Focused Drug Development (PFDD), with a particular emphasis on its application in the context of rare diseases.

Patient well-being extends beyond mere biological and symptomatic aspects of illness, encompassing factors such as daily functionality, healthcare access, health perceptions, and overall quality of life. Depending on the severity and prognosis of a disease, there may exist trade-offs between enhancing the biological and physiological aspects of the condition and improving the patient's day-to-day functioning and quality of life.

As the pharmaceutical industry increasingly adopts a patient-centric approach to drug development, real-world data plays a pivotal role in shaping both medical product development and regulatory decision-making. Developing a patient-focused strategy requires researchers to gain a profound understanding of various facets of the patient experience, including their primary concerns, the disease's burden, and the effectiveness of existing treatments.

Discover how these factors can vary between individuals and diseases, underscoring the importance of considering them separately for each specific medical condition under examination, and how to utilize these findings when crafting your next clinical development program.